Eli Lilly and Company (LLY)
Eli Lilly: Zepbound Price Cuts Have Multiple Positives, Limited Downside
Eli Lilly's weight loss treatment Zepbound might be a blockbuster in the making, but it wasn't without its challenges. The company faced criticism for high prices, supply blockages and the rise of counterfeits. It has now addressed all these concerns. Zepbound's price cuts can make at least some customers happy, its latest packaging allows for bigger supplies, and the online portal can reduce the use of non-prescription medication.
Eli Lilly partner BioAge files for US IPO
BioAge Labs, a biotech startup collaborating with Eli Lilly for its obesity therapy, said on Tuesday it had filed for an initial public offering in the United States.
3 No-Brainer Stocks to Buy in September
Eli Lilly is a growth machine that never runs out of opportunities. Novo Nordisk is still gaining momentum.
Think Eli Lilly Stock Has Peaked? These 10 Words From the CEO May Change Your Mind
Eli Lilly has been rolling out Zepbound in recent months, and demand has been "unbelievable," says the CEO. Sales have been taking off, and that's even without spending aggressively on sales and marketing.
Lilly (LLY) Is Considered a Good Investment by Brokers: Is That True?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Hims & Hers Health Stock Takes Hit as Eli Lilly Offers Cheaper Weight-Loss Drug
Shares of Hims & Hers Health (HIMS) sank in intraday trading Tuesday on new competition for lower-priced weight-loss drugs from Eli Lilly (LLY).
Eli Lilly Launches Cheaper Single-Use Vials of Weight-Loss Drug Zepbound
Eli Lilly (LLY) reached a key supply milestone Tuesday, announcing the launch of single-dose vials of Zepbound, one of the company's popular weight-loss drugs.
Eli Lilly just halved the price of its weight-loss drug — declaring war on the booming market of knock-offs
Eli Lilly is cutting the price of its popular weight-loss drug to compete with counterfeit weight-loss drugs. Zepbound will be sold for $399-$549 per month, compared to a previous list price of $1,059.
Eli Lilly's Stock Keeps Looking Better and Better. Here's the Latest Reason Why.
Its tirzepatide reduces the chance of developing diabetes, according to a new study. The population of people who might develop diabetes in the future is very large.
Eli Lilly Halves Zepbound Price In New Version Of Weight-Loss Drug
Eli Lilly will offer weight-loss drug Zepbound in a new form at roughly half the list price. Eli Lilly stock fell, along with several others.
Eli Lilly says patients can now access 2.5 mg and 5 mg vials of weight-loss drug Zepbound for at least 50% discount
Eli Lilly & Co. LLY, -0.23% said Tuesday patients can now access 2.5 mg and 5 mg single-dose vials of its weight-loss treatment Zepbound with an on-label prescription at a discount of at least 50% over other incretin medicines for obesity. The drug company said the vials are available through its LillyDirect self-pay channel.
Lilly launches single-dose vials of Zepbound for weight loss to expand US supply
Eli Lilly said it has begun selling single-dose vials of its popular weight-loss drug Zepbound in the U.S., aimed at patients who cannot get the cost of the medicine reimbursed through their health insurance plans.
